<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39331323</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".</ArticleTitle><Pagination><StartPage>2463</StartPage><EndPage>2467</EndPage><MedlinePgn>2463-2467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01054-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takazono</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Satoki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan. satoki.fujita@shionogi.co.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komeda</LastName><ForeName>Takuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazawa</LastName><ForeName>Shogo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitanishi</LastName><ForeName>Yoshitake</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Huilian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uehara</LastName><ForeName>Takeki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Drug Development and Regulatory Science Division, Shionogi &amp; Co., Ltd., Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosogaya</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwanaga</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukae</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Ensitrelvir</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Japanese nationwide database</Keyword></KeywordList><CoiStatement>Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, Masahiro Kinoshita, Satoshi Kojima, Huilian Shen, and Takeki Uehara are employees of Shionogi &amp; Co., Ltd. and may hold stocks in the company. Takahiro Takazono has received personal fees from Shionogi &amp; Co., Ltd., MSD K.K., Pfizer Japan Inc., Insmed GK., Asahi Kasei Pharma Corporation, and Kyorin Pharmaceutical Co., Ltd. Hiroshi Mukae has also received personal fees from AbbVie GK., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., FUJIFILM Toyama Chemical Co., Ltd., Gilead Sciences Inc., Insmed GK., Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Nihon Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Sumitomo Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Taisho Pharma Co., Ltd., Teijin Healthcare Ltd., and Toa Shinyaku Co., Ltd., and grants from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., FUJIFILM Toyama Chemical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Toa Shinyaku Co., Ltd., and Torii Pharmaceutical Co., Ltd., outside the submitted work. Naoki Hosogaya and Naoki Iwanaga have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331323</ArticleId><ArticleId IdType="pmc">PMC11499536</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01054-6</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01054-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hagiya H. Comment on “Real-world, retrospective comparative cohort study of severe outcomes in covid-19 outpatients at high risk of severe illness treated with ensitrelvir or no antiviral treatment”.</Citation></Reference><Reference><Citation>Takazono T, Fujita S, Komeda T, et al. Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19. Infect Dis Ther. 2024;13:1821–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11266320</ArticleId><ArticleId IdType="pubmed">38941067</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387(9):790–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19–United States, April–September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9721144</ArticleId><ArticleId IdType="pubmed">36454693</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. Clinical course and management of COVID-19 in the era of widespread population immunity. Nat Rev Microbiol. 2024;68(22):75–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">38114838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>